The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 14 of the 40 sources its claims cite were checked for support.
APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases
Open accessAbstract
A patient with the PSEN1 E280A mutation and homozygous for APOE3 Christchurch (APOE3Ch) displayed extreme resistance to Alzheimer’s disease (AD) cognitive decline and tauopathy, despite having a high amyloid burden. To further investigate the differences in biological processes attributed to APOE3Ch, we generated induced pluripotent stem (iPS) cell-derived cerebral organoids from this resistant case and a non-protected control, using CRISPR/Cas9 gene editing to modulate APOE3Ch expression. In the APOE3Ch cerebral organoids, we observed a protective pattern from early tau phosphorylation. ScRNA sequencing revealed regulation of Cadherin and Wnt signaling pathways by APOE3Ch, with immunostaining indicating elevated β-catenin protein levels. Further in vitro reporter assays unexpectedly demonstrated that ApoE3Ch functions as a Wnt3a signaling enhancer. This work uncovered a neomorphic molecular mechanism of protection of ApoE3 Christchurch, which may serve as the foundation for the future development of protected case-inspired therapeutics targeting AD and tauopathies.
Overview
CoChat Summary
TL;DR
In iPS cell-derived cerebral organoids from a PSEN1 E280A APOE3 Christchurch homozygous protected case and a non-protected control, APOE3Ch was associated with reduced early pTau S396 and increased β-catenin/Wnt/Cadherin signaling. ApoE3Ch unexpectedly enhanced Wnt3a reporter signaling, suggesting a neomorphic protective mechanism.
Key findings
- APOE3Ch cerebral organoids showed a protective pattern of early tau phosphorylation: pTau S396 was reduced, and removal of APOE3Ch increased pTau S396; effects were independent of PSEN1 genotype. Quantification used 3–4 organoids per line, with n = 31–159 measurements for patient α and n = 25–47 for patient ω.
- scRNA-seq, downsampled to 6,400 cells per dataset, implicated Wnt and Cadherin signaling; APOE3Ch drastically decreased transcript levels of WNT2B, WNT4, and WNT7B but did not influence β-catenin transcript.
- β-catenin was significantly increased in APOE3Ch organoid rosette body and ribbon. In postmortem patient α brain, nuclear β-catenin colocalization was significantly higher in frontal cortex than hippocampus and occipital cortex (p < 0.0001 for both), while neuronal β-catenin colocalization differed only between hippocampus and occipital cortex (p = 0.025).
- In a TCF/LEF Wnt reporter assay, ApoE3Ch alone did not induce Wnt signaling, but when combined with Wnt3a it acted as a Wnt signaling activator, whereas ApoE3WT functioned as a Wnt signaling inhibitor; a repeated experiment confirmed a dose-dependent relationship.
Methods
- Two Paisa kindred women were studied: Patient α was the APOE3Ch homozygous protected case who developed MCI in her seventies; Patient ω was an APOE3WT PSEN1 E280A non-protected control who developed MCI and dementia in her forties. Blood cells were reprogrammed to iPS cells and CRISPR/Cas9-edited to add or remove APOE3Ch and PSEN1 E280A, generating eight cell lines; cerebral organoids were analyzed 29 days after EB spheroid formation.
- scRNA-seq was performed on six pooled organoids per cell line using 10X Genomics; data were processed with Seurat, SCTransform, Harmony, DoubletFinder, PANTHER, GSEA, SCSA, and Monocle. Immunostaining was quantified in MATLAB, and Wnt signaling was tested in HEK293 TCF/LEF luciferase reporter cells with LiCl, recombinant ApoE proteins, and Wnt3a, using one-way ANOVA with Tukey’s post-hoc test.
Limitations
- Stated: further studies with more mature organoids are needed to confirm that the protective tau phosphorylation pattern persists over time; Wnt validation relied only on the HEK293 system; CRISPR off-target effects cannot be ruled out despite isogenic controls; developmental patterns of tau phosphorylation may confound results; and cluster cell identification is limited by continuous gene expression patterns.
- Stated/evident: genetic imputation of causality was not feasible because only a single APOE3Ch homozygote resistant case had been identified, and the study used a small number of patients and cell lines.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
10 Valid · 0 Not valid · 16 Not checked · 74 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A patient with the PSEN1 E280A mutation and homozygous for APOE3 Christchurch (APOE3Ch) displayed extreme resistance to Alzheimer’s disease (AD) cognitive decline and tauopathy, despite having a high amyloid burden.”
- Also stated in: § Introduction · plain
“She had very limited levels of tau pathology, neuroinflammation, and neurodegeneration but extremely high levels of amyloid plaque burden (Arboleda-Velasquez et al., 2019; Sepulveda-Falla et al., 2022; Lopera et al., 2023).”
§ APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases > Abstract
What the sources say
- Supportedcites Arboleda-Velasquez et al., 2019 source
The paper reports that this PSEN1 E280A carrier was homozygous for APOE3 Christchurch and did not develop mild cognitive impairment until her seventies, nearly three decades later than typical (Abstract). Its neuroimaging findings report unusually high amyloid plaque burden but relatively limited tau burden; resistance to tauopathy here does not mean tau was absent (Abstract, neuroimaging findings). (LLM, conf=0.92)
- Supportedcites Sepulveda-Falla et al., 2022 sourceExperimental — accuracy not yet measured
Initial resolution matched the wrong record for 'Sepulveda-Falla et al., 2022'; re-pointed to 'Resistance to autosomal dominant Alzheimer’s in an APOE3-Christchurch homozygote: a case report', whose authors and year match the citation; checked there. The cited paper directly describes a PSEN1 E280A carrier with two APOE3 Christchurch copies who remained free of Alzheimer’s symptoms until her seventies, nearly three decades beyond the kindred’s typical onset. Its paper-scoped snippet reports severely elevated brain amyloid-β alongside limited tau pathology (score 0.718). The resistance was not absolute: the paper also documents later cognitive decline and substantial tau pathology in the occipital cortex. (LLM, conf=0.93)
- Not matchedcites Lopera et al., 2023
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with a more mature phenotype, APOE3Ch organoids stained prominently with Reelin, a marker of more mature neurons (Figures 4A–D; Lancaster et al., 2013; Di Lullo and Kriegstein, 2017).”
§ APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases > Results > β-Catenin is elevated in APOE3Ch cerebral organoids
What the sources say
- Partly supportedcites Lancaster et al., 2013 sourceExperimental — accuracy not yet measured
In Results, “Formation of functional cerebral cortical neurons” (page unavailable), Lancaster et al. report Reelin-positive neurons in 30-day organoids and interpret them as possible Cajal–Retzius cells. They do not describe Reelin as a marker of more mature neurons or study APOE3Ch organoids; the APOE3Ch staining is the citing paper’s own result. (LLM, conf=0.87)
- Supportedcites Di Lullo and Kriegstein, 2017 sourceExperimental — accuracy not yet measured
Di Lullo and Kriegstein (2017) describes organoids with a region containing Reelin-positive cells, supporting the citation’s background point about Reelin staining in developing organoids. It does not report the APOE3Ch staining result. That result appears in “APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases” (unscoped match score 0.623), which cites Di Lullo and Kriegstein in the same sentence. The citation is therefore reasonable as background support, not as the source of the APOE3Ch experiment. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Three brain areas were selected as representative for the degree of protection conferred by this APOE mutation: frontal cortex (FC), hippocampus (Hipp), and occipital cortex (OC) (Sepulveda-Falla et al., 2022).”
§ APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases > Results > Increased nuclear β-catenin in neurons of protected brain regions of patient α
What the sources say
- Supportedcites Sepulveda-Falla et al., 2022 source
The Results (Fig. 2 caption; page unavailable) identify frontal cortex, hippocampus, and occipital cortex as the three regions compared in the cellular analysis. The Discussion describes a frontal-to-occipital gradient associated with regional differences in pathology and protection, supporting their use to represent differing degrees of protection in this patient. (LLM, conf=0.88)
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This finding bolsters our previous suggestion for an APOE dose-dependent protective effect (Sepulveda-Falla et al., 2022).”
§ APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases > Discussion
What the sources say
- Supportedcites Sepulveda-Falla et al., 2022 source
The Discussion explicitly says that regional differences in APOE expression support the idea of a dose-dependent mechanism of protection. It presents this as a suggestion, consistent with the citing sentence, rather than as a proven causal effect. (LLM, conf=0.92)
boostedstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Due to the expression of APOE from glial cells, we queried these cell clusters revealing also Wnt signaling and Cadherin signaling, among others (Figure 3G).”
§ APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases > Results > Single-cell RNA sequencing of cerebral organoids reveals Wnt signaling differences
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
38 more claims
Create a free account to see all 100 claims and to verify the 24 references still open.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings are consistent with prior observations in isogenic induced pluripotent stem cell (iPSC)‐derived brain organoids, where the APOE3Ch variant enhanced Wnt3a signaling and increased expression of β‐catenin target genes, despite exhibiting reduced levels of Wnt ligands. 8”
From Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease (2026) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent cerebral organoid studies demonstrated that APOE3ch modulates β-catenin/Wnt and cadherin pathways in PS1E280A backgrounds, mirroring our findings in 2-D neural cultures (Perez-Corredor et al., 2024).”
From Isogenic human stem cell models reveal mutation-dependent protective mechanisms of APOE3 Christchurch (2026) · cites this paper as Perez-Corredor et al., 2024
The cited source says what the claim attributes to it.
In the citing paper
“and enhances Wnt/β‐catenin signaling, a pathway critical for neuronal homeostasis. 8”
From Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“ApoE, identified as an upstream regulator in PSEN1E280A ‐APOE3Ch vesicles, may indicate that vesicular ApoE3Ch modulates intracellular signaling pathways, including the activation of Wnt/β‐catenin signaling, 8 which supports BBB integrity through junctional stabilization and transcriptional regulation 76 and limits immune infiltration. 67”
From Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Recent work shows that ApoE3Ch modulates Wnt pathway sensitivity by altering interactions with tau and reducing responsiveness to the Wnt inhibitor DKK1, 61 a mechanism also observed in APOE3Ch iPSC‐derived organoids that exhibit reduced tau pathology. 8”
From Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease (2026) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases > Results > Increased nuclear β-catenin in neurons of protected brain regions of patient α
“Bar graphs for colocalization analysis depicting TCVs between DAPI and β-catenin in FC, Hipp, and OC. The percentage of β-catenin colocalizing with neurons is significantly higher only in Hipp when compared to OC (one-way ANOVA, p = 0.025) (C).”
§ APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases > Results > Increased nuclear β-catenin in neurons of protected brain regions of patient α
“we performed colocalization analysis between β-catenin, DAPI as a nuclear marker, and NeuN as a neuronal marker.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases > Results > Single-cell RNA sequencing of cerebral organoids reveals Wnt signaling differences
“APOE displays minimal transcript expression in neuronal clusters and is enriched in glial Clusters 5 and 8 (Supplementary Figure 4), as expected.”
§ APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases > Results > Single-cell RNA sequencing of cerebral organoids reveals Wnt signaling differences
“neuronal clusters 0, 1, 8, 10, 12, 13, and 14 (F), and glia-type clusters 3, 5, and 7 (G).”
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Integrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508
Fast, sensitive and accurate integration of single-cell data with Harmony
Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.-R., & Raychaudhuri, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0619-0 · Cited by 10,488 · cited 1×
“Sample integration was accomplished by merging Seurat objects with merge(), v.1 SCTransform() (Hafemeister and Satija, 2019) with FindClusters (resolution = 0.3) and Harmony integration [RunHarmony()] (Korsunsky et al., 2019).”
MethodInfluentialCerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372
Reversed graph embedding resolves complex single-cell trajectories
Qiu, X., Mao, Q., Tang, Y., Wang, L., Chawla, R., Pliner, H. A., & Trapnell, C. (2017) · Nature Methods · doi:10.1038/nmeth.4402 · Cited by 5,070 · cited 1×
“Monocle (Qiu et al., 2017) was employed for single-cell trajectory analysis and identification of genes that change as a function of pseudotime.”
MethodMcGinnis, C. S., Murrow, L. M., & Gartner, Z. J. (2019) · Cell Systems · doi:10.1016/j.cels.2019.03.003 · Cited by 4,521
Hafemeister, C., & Satija, R. (2019) · Genome Biology · doi:10.1186/s13059-019-1874-1 · Cited by 4,479 · cited 4×
“Cell line scRNA-seq UMAP cluster characteristics. scRNAseq data were downsampled and integrated using SCTransform and Harmony.”
MethodInfluentialKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606 · cited 1×
“…and tau tangles in the brain as well as calcium and mitochondrial dysregulation that Perez-Corredor et al. 10.3389/fnmol.2024.1373568 Frontiers in Molecular Neuroscience 02 frontiersin.org manifests in neuronal death and memory deficits (Nunomura et al., 2001; Mosconi, 2013; Knopman et al., 2021).”
BackgroundInfluentialOxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885
Wnt signal transduction pathways
Komiya, Y., & Habas, R. (2008) · Organogenesis · doi:10.4161/org.4.2.5851 · Cited by 1,528 · cited 1×
“Wnt signaling influences multiple cellular processes such as cell fate determination, cell polarity, organogenesis, stem cell renewal (Komiya and Habas, 2008), neuronal health (Inestrosa and (Wang et al., 2022).”
Background
Cited by
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Factors Affecting Resilience and Prevention of Alzheimer's Disease and Related Dementias
Masurkar, A. V., Marsh, K., Morgan, B. E., Leitner, D., & Wısnıewskı, T. (2024) · Annals of Neurology · doi:10.1002/ana.27055 · Cited by 46
“102 A better understanding of this variant may inform therapeutic studies, something currently undergoing investigation.”
Sun, G. G., Wang, C., Mazzarino, R. C., Perez-Corredor, P. A., Davtyan, H., Blurton-Jones, M., Lopera, F., Arboleda-Velasquez, J. F., & Shi, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114982 · Cited by 36
Self-citationRecent advances in neuroimaging of Alzheimer's disease and related dementias
Ottoy, J., Owsicki, N., Bilgel, M., Binette, A. P., Salvadó, G., Kang, M. S., Cash, D. M., Ewers, M., Joie, R. L., Wisse, L. E. M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70648 · Cited by 39
“167 The rare APOE ε 3 Christchurch ( APOE3 Ch ) variant (R136S) has been identified as protective in ADAD, 168,169 delaying neurodegeneration and tau PET uptake, even in the presence of A β PET positivity.”
CRISPR/Cas9 and iPSC-Based Therapeutic Approaches in Alzheimer’s Disease
Raffaele, I., Cipriano, G. L., Anchesi, I., Oddo, S., & Silvestro, S. (2025) · Antioxidants · doi:10.3390/antiox14070781 · Cited by 33
“…off-target) and standardization, coupled with the complex ethical and legal considerations of human gene editing and stem cell use, represent significant difficulties that must be addressed before these technologies can be widely translated into effective clinical interventions for AD [105,143].”
Influential
Metadata
- Authors
- Perez-Corredor, P., Vanderleest, T. E., Vacano, G. N., Sanchez, J. S., Villalba-Moreno, N. D., Marino, C., Krasemann, S., Mendivil-Perez, M. A., Aguillón, D., Jiménez-Del-Río, M., Baena, A., Sepulveda-Falla, D., Lopera, F., Quiroz, Y. T., Arboleda-Velasquez, J. F., & Mazzarino, R. C.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- Harvard University (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Universidad de Antioquia (CO)
- Corresponding author
- Mazzarino, Randall C.
- ORCID
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2024-03-20
- Volume
- 17
- Pages
- 1373568-1373568
- ISSN
- 1662-5099 (ISSN-L)
- PMC
- PMC10987717
- OpenAlex
- W4393013786
- Cited by
- 28
- References
- 54
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 8
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Molecular Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute on Aging (RF1 NS110048)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- Alzheimer's disease, PSEN1 E280A mutation, brain organoids, induced pluripotent stem cells, Wnt3a, tau phosphorylation, tauopathy, amyloid burden, CRISPR/Cas9 genome editing, single-cell RNA sequencing, cadherin signaling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases. https://app.cochat.ai/papers/10.3389/fnmol.2024.1373568
- The paper
- Perez-Corredor, P., Vanderleest, T. E., Vacano, G. N., Sanchez, J. S., Villalba-Moreno, N. D., Marino, C., Krasemann, S., Mendivil-Perez, M. A., Aguillón, D., Jiménez-Del-Río, M., Baena, A., Sepulveda-Falla, D., Lopera, F., Quiroz, Y. T., Arboleda-Velasquez, J. F., & Mazzarino, R. C. (2024). APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases. Frontiers in Molecular Neuroscience. https://doi.org/10.3389/fnmol.2024.1373568
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.